{
    "clinical_study": {
        "@rank": "53769", 
        "arm_group": {
            "arm_group_label": "Novaferon+ xeloda", 
            "arm_group_type": "Experimental", 
            "description": "Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).\nRecombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor\n      and anti-virus protein for injection plus capecitabine in treating patients with metastatic\n      colorectal cancer who have progressed after standard therapy."
        }, 
        "brief_title": "Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a Phase \u2161 exploratory clinical study. The purpose of this study is to evaluate the\n      efficacy and safety of recombinant anti-tumor and anti-virus protein for injection plus\n      capecitabine in treating patients with metastatic colorectal cancer who have progressed\n      after standard therapy.\n\n      All patients will receive recombinant anti-tumor and anti-virus protein for injection and\n      capecitabine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged above 18 years.\n\n          -  Pathologically confirmed metastatic adenocarcinoma of the colon or rectum. All other\n             histological types are excluded.\n\n          -  Failure of Second-Line and more than second-line treatment, and fluoropyrimidine- and\n             irinotecan- and oxaliplatin-containing regimens.(Subjects who progress during or\n             within 3 months following the last administration of approved standard therapies and\n             terminate standard treatment due to unacceptable toxicity warranting.).If recurrence\n             and metastasis occurred within 6 months after discontinuation of adjuvant\n             chemotherapy, the adjuvant chemotherapy is considered to be first-line\n             treatment.Subject received last-line treatment not including capecitabine.\n\n          -  At least one measurable lesion according to the RECIST criteria that has not been\n             previously local treated. Minimum indicator lesion size as follows: greater than or\n             equal to 10 mm measured by spiral CT or NMR.Malignant lymph nodes short diameter as\n             follows: greater than or equal to 15 mm measured by spiral CT.\n\n          -  ECOG performance status 0, 1 or 2.\n\n          -  Minimum of 4 weeks since any local radiotherapy or surgery for the control of\n             symptoms or severe complications(local radiotherapy for the control of bone\n             metastases is not the limit)\uff0cand adequately recovered from toxicities of any prior\n             therapy).\n\n          -  Life expectancy of at least 3 months.\n\n        Exclusion Criteria:\n\n          -  Prior treatment with novaferon.\n\n          -  Pregnancy or breast-feeding women or women who may be pregnant were positive drug\n             test before administration.\n\n          -  Patient of child-bearing potential(male or less than 1 year postmenopausal women)\n             were reluctant to take contraceptive measures.\n\n          -  Patient who were allergic to Interferon-\u03b1 or who had interferon-\u03b1 antibody.\n\n          -  Patients with uncontrolled central nervous system (CNS) metastases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02068131", 
            "org_study_id": "JH-RC-006"
        }, 
        "intervention": [
            {
                "arm_group_label": "Novaferon+ xeloda", 
                "description": "Recombinant anti-tumor and anti-virus protein for injection, 10\u03bcg, im, 3 times per week for first 2 weeks, followed by 20\u03bcg,im, 3 times per week after 2 weeks.", 
                "intervention_name": "Novaferon", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Novaferon+ xeloda", 
                "description": "The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Brand name:Xeloda"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Capecitabine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic Colorectal Cancer", 
            "Novaferon", 
            "Recombinant anti-tumor and anti-virus protein for injection", 
            "xeloda"
        ], 
        "lastchanged_date": "February 20, 2014", 
        "location": {
            "contact": {
                "email": "jmxu2003@yahoo.com", 
                "last_name": "Xu Jianming", 
                "phone": "+861051128358"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100071"
                }, 
                "name": "307 Hospital of PLA"
            }, 
            "investigator": {
                "last_name": "Xu jianming, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Recombinant Anti-tumor and Anti-Virus Protein for Injection Plus Capatabine in Treating Patients With Metastatic Colorectal Cancer After Failure of Standard Treatment", 
        "overall_contact": {
            "email": "jmxu2003@yahoo.com", 
            "last_name": "Xu Jianming, M.D.", 
            "phone": "+861051128358"
        }, 
        "overall_official": {
            "affiliation": "307 Hospital of PLA", 
            "last_name": "Xu Jianming, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ORR is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments.", 
            "measure": "Overall response rate(ORR)", 
            "safety_issue": "No", 
            "time_frame": "every 6 weeks until disease progression,assessed up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02068131"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "DCR is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments.", 
                "measure": "Disease control rate(DCR)", 
                "safety_issue": "No", 
                "time_frame": "every 6 weeks until disease progression,assessed up to 6 months"
            }, 
            {
                "description": "PFS is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "every 6 weeks until disease progression,assessed up to 6 months"
            }, 
            {
                "description": "OS is defined as the length of time from random assignment to death or to last contact.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "every 8 weeks until death,assessed up to 2 years"
            }, 
            {
                "description": "AEs are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.", 
                "measure": "Adverse Events(AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "from informed consent form signed to 30 days after termination of administration,assessed up to 6 months"
            }
        ], 
        "source": "The Affiliated Hospital of the Chinese Academy of Military Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Affiliated Hospital of the Chinese Academy of Military Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}